Epcoritamab plus R-CHOP Phase 3 results: Can AbbVie stock break $279.47 resistance?

Traders Union
All News
Stocks
AbbVie jumps 3.02% after trial success

Highlights

AbbVie and Genmab reported their epcoritamab plus R-CHOP regimen reduced risk of disease progression or death by 51% in Phase 3 diffuse large B-cell lymphoma trials.
The successful trial result brings renewed market focus to AbbVie’s oncology portfolio and the company’s role in novel patient therapies.
Shares of AbbVie climbed to $274.75, gaining 3.02% on strong bullish momentum, with a projected trading range of $270.03 to $279.47 and overbought signals suggesting a near-term pause.

Positive trial data boosts sentiment as oncology leadership expands

AbbVie and Genmab have reported successful Phase 3 trial outcomes for their epcoritamab plus R-CHOP regimen in newly diagnosed diffuse large B-cell lymphoma, showing a 51% reduction in risk of disease progression or death compared to standard treatment, according to Finance Yahoo. This significant clinical result is driving renewed interest in AbbVie's expanding oncology portfolio by underlining the company's leadership in delivering novel therapies with tangible patient outcomes. As investors respond to the robust data, the news acts as a catalyst for positive sentiment and supports further enthusiasm in the market.

Bullish momentum persists as overbought signals hint at pause risk

On the technical front, price action remains robust above the MA-20 of $264.59 and MA-50 of $263.73 on the hourly chart, and well above the MA-200 at $231.94 on the daily timeframe. The Ichimoku Kijun sits at $264.39 and now serves as immediate support. MACD continues to show a Buy bias, while ADX appears neutral. RSI at 67.45 signals sustained bullishness, but Stoch RSI, CCI, and Bull/Bear Power all point to overbought conditions and prevailing buyer dominance during intraday trading. The Awesome Oscillator reinforces the current bullish trend, though the convergence of overbought signals highlights an emerging divergence and the possibility of a short-term pause.

Sideways trading forecast as volatility boundaries limit price breakout

Looking ahead, ABBV is expected to remain range-bound over the next 2–3 trading days within a typical volatility band between $270.03 and $279.47. Based on current momentum and indicator setups, the probability of further upside moves is estimated at 79%, with a 21% chance of a pullback. The baseline scenario anticipates sideways trading within this range. A close above $279.47 could trigger additional gains, while a break below $270.03 would signal a short-term reversal and test immediate support.

Anton Kharitonov, expert at Traders Union, sees further upside in ABBV supported by strong clinical data and sustained technical momentum. He notes that price action above key averages and bullish indicators are positive, but warns of signs of short-term exhaustion as technical signals look overbought. Base case remains range trading between $270.03 and $279.47 in the near term, with defensiveness warranted if support is lost. "Until ABBV decisively clears $279.47, I remain cautious and watch for a potential pause or reversal."

Earlier, analysts noted that AbbVie was likely to maintain an upward bias supported by regulatory progress and pipeline developments. The latest clinical trial success and continued technical strength further reinforce the prevailing bullish scenario, with attention now on price action near the $279.47 resistance level as a possible catalyst for additional upside movement.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.